Open AccessAbiraterone acetate – 10 clinically relevant facts
Author(s) -
Jakub Żołnierek
Publication year - 2021
Publication title -
oncoreview
Language(s) - English
Resource type - Journals
eISSN - 2450-6125
pISSN - 2353-852X
DOI - 10.24292/01.or.123300921.1
Subject(s) - abiraterone acetate , prostate cancer , abiraterone , medicine , oncology , population , drug , cancer , mechanism of action , systemic therapy , androgen receptor , pharmacology , bioinformatics , androgen deprivation therapy , biology , biochemistry , environmental health , breast cancer , in vitro
Prostate cancer is one of the most frequently diagnosed cancers in men. Number of newly diagnosed cases is increasing due to several factors and the most important ones seem to be: population ageing and more sensitive diagnostic procedures. Secondary – the higher efficacy of treatment with its influence on improving patients’ overall survival and the specific mechanism of action of drugs used in systemic therapy lead to growing population of men suffering from prostate cancer in general and, specifically – patients with castration resistance. It is hormone therapy to play the key role in systemic treatment of prostate cancer with increasing significance of novel drugs focused on inhibition of molecular signal transduction mediated by androgen receptor. Abiraterone acetate is the representative of this therapeutic class. The paper describes the most clinically relevant data regarding the drug.